Boulevard Bio, Inc.

Boulevard Bio is a precision immunology company built to change the course of B cell-driven autoimmune diseases with targeted, multi-specific medicines designed to set new therapeutic standards. Boulevard is advancing a pipeline of multi-specific antibodies grounded in a deep understanding of B cell disease biology to pair the right targets and modalities to the right disease across the spectrum of B cell-driven autoimmune conditions. The company was founded by pioneers in B cell biology and was incubated by Deerfield Management with molecules developed inside Deerfield Discovery and Development (3DC), the firm’s internal therapeutics research and development engine. The company’s corporate headquarters are in New York City at Cure, an affiliate of Deerfield.